FAM
NBIX icon

Formidable Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Formidable Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,400
Closed -$386K – 301
2019
Q1 		$386K Buy
+4,400
New +$368K 0.15% 115

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Formidable Asset Management's NBIX Position: Q2 2019 in Review

Formidable Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 4,400 shares — an estimated $386K sold.

Formidable Asset Management first reported a position in NBIX in Q1 2019 and held it in 1 quarter. The position peaked at $386K in Q1 2019. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Formidable Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • Formidable Asset Management sold 4,400 Neurocrine Biosciences shares in Q2 2019, an estimated $386K.
  • Formidable Asset Management first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 1 quarter.
  • Formidable Asset Management's Neurocrine Biosciences position peaked at $386K in Q1 2019.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Formidable Asset Management's 13F filing for Q2 2019, filed 15 Oct 2019.